Guj. Themis Bio. (GUJTHEM)

FairStock Score: 19/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Guj. Themis Bio., I first ask: what kind of business am I buying? The numbers show a company earning a return on equity of 21.39% and a return on capital employed of 27.29%. That is genuinely impressive. It tells me management has historically used shareholder money well. Debt is low, at just 0.27 times equity, so the balance sheet is not keeping me up at night. Promoters hold 70.86%, so their interests are aligned with mine. That part I like. But then I turn to valuation and growth. Sales grew only 9.74%, and profit actually fell 3.93% in the latest year. A business growing sales but not profits is getting less efficient, or facing pricing pressure. The latest quarter shows sales of ₹43 Cr and net profit of ₹12 Cr, so roughly a 28% net margin, but I need to see that sustained. The price is ₹324.42, and I am being asked to pay 70.31 times earnings and 15.60 times book value. Book value is just ₹20.79. That leaves no margin of safety whatsoever. Graham would shake his head. The dividend yield is a token 0.22%, so patience is not rewarded while I wait. The Piotroski F-Score of 4 out of 9 and FairStock Score of 12/100 only reinforce my caution. PEG of 7.22 tells me the market is pricing in far more growth than this business is delivering. This is not a wonderful business at a fair price; it is a decent business at a very demanding price. I would keep it on my watchlist, but I would not buy today.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer